CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) —


Fulcrum Therapeutics, Inc.


(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel 2022 Biotech Summer Summit, on Wednesday, August 17, 2022 at 11:30 a.m. ET.

About Fulcrum Therapeutics


Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit


www.fulcrumtx.com


.

Contacts:

Investors


Stephanie Ascher

Stern Investor Relations, Inc.

[email protected]

212-362-1200

Media


Dee Smith

Executive Director, Corporate Communications

Fulcrum Therapeutics, Inc.

[email protected]

202-746-1324